A companion diagnostic is a test that is developed, validated, and often co-approved alongside a specific therapeutic drug to identify patients who are likely to respond to that drug — and, equally importantly, to identify those who are not. The defining characteristic of a companion diagnostic is that its clinical use is inseparable from a specific therapy: the test does not stand alone as a general screening or monitoring tool. It exists to answer one question — should this patient receive this treatment?
The regulatory definition matters here. The FDA defines a companion diagnostic as an in vitro diagnostic device that provides information essential to the safe and effective use of a corresponding therapeutic product. That coupling — between the diagnostic result and the therapeutic decision — is what distinguishes a companion diagnostic from other molecular tests that might measure the same biomarker for different purposes.
Why Companion Diagnostics Exist
The premise behind companion diagnostics is straightforward: not all patients with the same diagnosis respond to the same therapy. Two patients with stage III non-small cell lung cancer may share a histopathological diagnosis, yet have tumors with fundamentally different molecular drivers — one with an EGFR activating mutation that makes it highly sensitive to an EGFR inhibitor, and one without that mutation, for whom the same drug would provide no benefit while still carrying its side effect burden.
Historically, clinical oncology operated on population-level averages — a therapy that worked in 30% of patients was approved based on that response rate, and all eligible patients received it, including the 70% for whom it did not work. Companion diagnostics are the mechanism by which precision medicine operationalizes the insight that the 30% who respond can, in many cases, be identified in advance. When they can, the clinical and economic logic is compelling: better outcomes for patients who receive effective treatment, reduced exposure for those who would not benefit, and more efficient allocation of expensive therapies.
How the FDA Classifies Companion Diagnostics
The FDA classifies most companion diagnostics as Class III medical devices, which require Premarket Approval (PMA) — the most rigorous pathway, requiring demonstration that the device is safe and effective for its intended use. A small number of companion diagnostics have been cleared through the 510(k) pathway based on substantial equivalence to a predicate device, but PMA is the standard for novel companion diagnostics tied to new molecular targets.
In the co-development model, the pharmaceutical company developing the therapy and the diagnostics company developing the companion diagnostic coordinate their regulatory submissions so that both are reviewed — and ideally approved — simultaneously. The FDA has issued guidance encouraging this co-development approach, and it has become standard practice for targeted oncology drugs entering pivotal trials. The companion diagnostic is enrolled in the clinical trial alongside the drug, and the trial data serves as the clinical validation for both the therapy and the test.
As of 2024, the FDA has approved more than 50 companion diagnostics. The majority are oncology-focused and detect genetic alterations — mutations, amplifications, fusions, or expression levels — that predict response to specific targeted therapies.
| Biomarker Source | Sample Type | Primary Analyte | Analytical Sensitivity | FDA-Approved Applications | MKA Strategic Implication |
|---|---|---|---|---|---|
| Tissue — IHC/FISH | Formalin-fixed tumor tissue | Protein expression; gene copy number / rearrangement | High for validated targets; spatial context preserved | PD-L1 expression (immunotherapy eligibility); HER2 amplification; ALK/ROS1 rearrangements | Tissue IHC/FISH remains the regulatory gold standard for expression-based CDx. Spatial context — knowing where in the tumor the biomarker is expressed — is a capability liquid biopsy cannot match. Any new CDx strategy should assess whether an IHC-based approach can satisfy the regulatory question before defaulting to molecular methods. |
| Tissue — NGS Panel | Formalin-fixed or fresh tumor tissue | Somatic mutations, copy number alterations, fusions, TMB, MSI | High; limited by tumor heterogeneity within biopsy specimen | Comprehensive tumor profiling (Foundation Medicine F1CDx, Tempus xT); NTRK fusion detection; MSI-H immunotherapy eligibility | Comprehensive NGS tissue panels are now a standard of care component in most major cancer types. The commercial landscape is consolidating around a small number of FDA-approved platforms. New entrants need a clearly differentiated clinical claim — a me-too panel without a novel biomarker focus faces difficult positioning. |
| ctDNA — Liquid Biopsy | Peripheral blood (plasma) | Circulating tumor DNA: somatic mutations, copy number, fusions | Lower than tissue in early-stage disease; improves with disease burden | EGFR mutation detection (NSCLC, Guardant360 CDx); BRCA1/2 (ovarian/prostate, FoundationOne Liquid CDx); RAS (colorectal) | ctDNA is the validated commercial anchor for liquid biopsy CDx. Most reimbursement pathways and coverage determinations are built around ctDNA evidence. New liquid biopsy CDx programs need to define their differentiation against ctDNA — whether on analyte class, cancer type, or application — not treat ctDNA as a parallel track. |
| CTCs | Peripheral blood | Intact circulating tumor cells: protein expression, genomic profile | Very low in early-stage disease; higher in metastatic setting | Metastatic breast, colorectal, prostate (CellSearch — FDA-cleared for prognosis, not CDx per se) | CTCs have not achieved CDx status despite decades of clinical investigation. Their primary value is prognostic, not predictive of specific therapy response. CTC-based CDx development faces a steep evidentiary climb — the clinical question they are best positioned to answer (treatment stratification in metastatic disease) is already being addressed by ctDNA in most programs. |
| Exosomes | Peripheral blood, urine, other body fluids | RNA cargo (mRNA, miRNA), surface proteins, DNA fragments | High abundance even in early-stage disease; membrane-protected cargo is more stable than free cfDNA | Investigational; growing number of FDA-cleared IVD products; active clinical trials in lung, breast, GI, and pancreatic cancers | Exosomes are the most commercially underdeveloped CDx source type with the most differentiated technical profile. Companies with early exosome CDx clinical data in hand are building a first-mover position before the regulatory pathway crowds. The surface protein capture strategy — which enables tumor-specific vesicle enrichment — is the differentiator to watch. |
Regulatory application data sourced from FDA IVD database and published companion diagnostic approvals. Clinical validation status reflects publicly available literature as of 2025. Strategic implications reflect MKA Insights analytical framework.
The Biomarker Sources Companion Diagnostics Use
Companion diagnostics draw on a range of biomarker types, depending on the biology of the target alteration and the therapeutic mechanism involved.
Tumor Tissue
Tissue-based companion diagnostics analyze genetic material extracted from a tumor biopsy. Immunohistochemistry (IHC) tests detect the presence and expression level of specific proteins in tumor tissue — PD-L1 expression testing, which guides eligibility for several checkpoint inhibitor therapies, is among the most widely used IHC-based companion diagnostics. Fluorescence in situ hybridization (FISH) detects gene amplifications and rearrangements. Next-generation sequencing (NGS) panels can interrogate hundreds of genes simultaneously, identifying mutations, copy number changes, fusions, and microsatellite instability status in a single test.
Liquid Biopsy Sources
Liquid biopsy-based companion diagnostics analyze circulating biomarkers in blood or other body fluids, capturing genetic information shed by tumor cells into the bloodstream. Three primary sources of biomarker material are used:
Circulating tumor DNA (ctDNA): fragments of DNA released by tumor cells into circulation. ctDNA carries the same mutations as the tumor of origin and can be detected and characterized with high-sensitivity sequencing methods. ctDNA-based companion diagnostics are FDA-approved for several indications, including EGFR mutation detection in non-small cell lung cancer.
Circulating tumor cells (CTCs): intact cancer cells that have shed from the primary tumor into the bloodstream. CTCs are informative across oncology applications but are present at very low frequency in early-stage disease, limiting sensitivity.
Exosomes: nanoscale extracellular vesicles secreted by cells — including tumor cells — that carry RNA, DNA, and proteins. Exosomes are stable in circulation, present at high abundance across disease stages, and can be targeted by cell-surface proteins to identify tumor-derived vesicles specifically. Exosome-based diagnostics are an active area of development, with several programs in clinical validation.
The clinical advantage of liquid biopsy-based companion diagnostics is their ability to capture tumor heterogeneity — including metastatic sites that may have evolved mutations not present in the primary biopsy sample — and to support serial testing over time without repeat tissue procedures.
Applications Beyond Initial Treatment Selection
Companion diagnostics were initially developed primarily to determine eligibility for a therapy at the start of treatment. That use case remains central, but the applications have expanded significantly.
Clinical Trial Screening
Precision oncology trials enroll patients based on molecular eligibility criteria rather than histopathological diagnosis alone. A companion diagnostic — or a closely related research-use assay — is used to screen prospective trial participants for the presence of the target alteration. The same assay used in trial enrollment may subsequently form the basis for the FDA-approved companion diagnostic that accompanies the approved therapy.
Monitoring Treatment Response and Resistance
As targeted therapies are used over time, tumors frequently develop resistance mutations that allow them to evade the mechanism of action of the drug. Serial testing using liquid biopsy can detect the emergence of resistance mutations earlier than imaging — providing an actionable signal that allows oncologists to consider switching therapy before clinical progression becomes apparent. Several liquid biopsy assays are approved or in development specifically for resistance monitoring.
Post-Market and Real-World Applications
Once a targeted therapy reaches the market, its companion diagnostic generates a continuous stream of real-world data on the prevalence of the target biomarker in the treated population, the distribution of co-mutations, and the clinical outcomes associated with different molecular profiles. This data can inform life cycle management strategies for both the therapy and the diagnostic — including label expansions, new indication submissions, and refined patient selection criteria.
The Strategic Relationship Between Pharma and Diagnostics
Co-development of a companion diagnostic with a targeted therapy creates a strategic partnership that is at once scientifically necessary and commercially complex. The diagnostic developer takes on substantial regulatory and clinical trial cost in exchange for a market that is defined entirely by the reach of the associated therapy. If the drug succeeds, the companion diagnostic succeeds with it. If the drug fails in pivotal trials, the companion diagnostic has no market.
This risk structure has driven consolidation in the companion diagnostics space. Large diagnostics companies with broad oncology portfolios — Roche, Foundation Medicine, Thermo Fisher, Guardant Health — are better positioned to absorb the clinical development cost of a companion diagnostic program than smaller, single-platform developers. Increasingly, pharma companies are selecting diagnostics partners early in development, sometimes at the preclinical stage, to ensure alignment on biomarker strategy before pivotal trial design is locked.
For life sciences companies navigating this landscape — whether as developers, partners, or advisors — the companion diagnostic is not a regulatory checkbox. It is a strategic asset that defines the eligible patient population, shapes payer negotiations, and determines the long-term commercial trajectory of the therapy it accompanies.